Table 2.

Treatment-emergent adverse events^*

Number of subjects (%)	Open-label	Double-blind
	Tolterodine ER (n = 990)	Placebo (n = 301)	Fesoterodine (n = 308)
Subjects with AEs
All-causality	134 (13.5)	75 (24.9)	110 (35.7)
Treatment-related	84 (8.5)	30 (10.0)	68 (22.1)
Discontinued because of AEs
All-causality	12 (1.2)	12 (4.0)	11 (3.6)
Treatment-related	7 (0.7)	6 (2.0)	7 (2.3)
Subjects with serious AEs	3 (0.3)	7 (2.3)	5 (1.6)
AE rates†
Dry mouth†	61 (6.2)	12 (4.0)	51 (16.6)
Constipation†	11 (1.1)	4 (1.3)	12 (3.9)

^*Includes data up to 7 days after last dose of study drug.

^†AEs occurring in ≥ 2% of subjects in any treatment group.